That's speak for no journal submission at all.
1. Can’t say if journal articles submitted or not.
Deflection on Sawston. The real question remains unasked and unanswered; What piece of the pie do retail own / receive?
Covid comment relayed is material to investment decision making.
2. Can’t say if Sawston inspection conducted yet or not, but can say Covid no longer seems to be an impediment to that process’s timeline.
So no journal publication means no TLD. I see.
The prestigious Dr Liau and UCLA could not explain it sufficiently so better to wait a year or two.
By now hundreds of people are in possession of TLD unless, of course, the data is still with the statisticians.
3. Can say that it appears they want TLD and Journal publication close together because they anticipate needing to clearly explain primary endpoints, because they are a recent innovation used by the FDA. This is essentially what Senti just said today or yesterday.
Another material leak on financing. The company states in the 10q they are a Going concern. The company allegedly /actually threw out a share price figure during said Quiet period. Can't make it up.
Reverse Split to $5 = "Easier".
4. Aren’t worried about needing financing anytime soon, but would be easier to finance at 5.00. (Note: I’d be totally fine with that, I bet I could almost speak for everyone on that, as long as it’s not obtained by a prerelease reverse split.)
More material leaks as it now somehow appears TLD is unrelated to Approval time line. Perhaps thousands are now in the know??
5, Last but not least, this is not about getting TLD out fast, according to DI, it is about trying to obtain approval, and a later public TLD announcement won’t slow down approval decision being made.
Material leaks...Quiet period breach...Nobody seems to care. Just give us something to talk about.
